Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions
Purpose: Patients with peripheral lung nodules require evaluation for lung cancer. Our aim is to assess the diagnostic yield of a new technique, transbronchial cryobiopsies, in patients at risk for lung cancer. Target population: Patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions. Procedures: Patients enrolled will have forceps transbronchial biopsies followed by transbronchial cryobiopsies for their lung lesion during bronchoscopy.
Checked against the public recordLast updated Mar 25, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Pennsylvania
- Interventions being studied
- Procedure: transbronchial biopsy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Age \>/= 18 2. At least one peripheral lung lesion \>8mm documented on CT scan referred for diagnostic bronchoscopy 3. Subject is able to undergo informed consent Exclusion Criteria: 1. Coagulopathy (platelet count \< 50,000, INR \> 1.5) detected on blood testing done within 6 weeks of the procedural visit 2. Lesion associated with a prominent vessel evident on CT scan 3. Pure ground glass lesion 4. Fibrotic interstitial lung abnormalities on chest CT 5. Bullous emphysema in region of nodule 6. Supplemental oxygen utilization at baseline 7. BMI \> 40 8. End stage renal disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 25, 2020. Always confirm current availability with the study team.